title: Investigation of the spatiotemporal responses of nanoparticles in tumor tissues with a small-scale mathematical model.
abstract: The transport and accumulation of anticancer nanodrugs in tumor tissues are affected by many factors including particle properties, vascular density and leakiness, and interstitial diffusivity. It is important to understand the effects of these factors on the detailed drug distribution in the entire tumor for an effective treatment. In this study, we developed a small-scale mathematical model to systematically study the spatiotemporal responses and accumulative exposures of macromolecular carriers in localized tumor tissues. We chose various dextrans as model carriers and studied the effects of vascular density, permeability, diffusivity, and half-life of dextrans on their spatiotemporal concentration responses and accumulative exposure distribution to tumor cells. The relevant biological parameters were obtained from experimental results previously reported by the Dreher group. The area under concentration-time response curve (AUC) quantified the extent of tissue exposure to a drug and therefore was considered more reliable in assessing the extent of the overall drug exposure than individual concentrations. The results showed that 1) a small macromolecule can penetrate deep into the tumor interstitium and produce a uniform but low spatial distribution of AUC; 2) large macromolecules produce high AUC in the perivascular region, but low AUC in the distal region away from vessels; 3) medium-sized macromolecules produce a relatively uniform and high AUC in the tumor interstitium between two vessels; 4) enhancement of permeability can elevate the level of AUC, but have little effect on its uniformity while enhancement of diffusivity is able to raise the level of AUC and improve its uniformity; 5) a longer half-life can produce a deeper penetration and a higher level of AUC distribution. The numerical results indicate that a long half-life carrier in plasma and a high interstitial diffusivity are the key factors to produce a high and relatively uniform spatial AUC distribution in the interstitium.
authors.affiliation: Department of Bio-Industrial Mechatronics Engineering, National Taiwan University, Taipei, Taiwan.
authors.forename: Cheng-Ying
authors.initials: CY
authors.lastname: Chou
authors.forename: Chih-Kang
authors.initials: CK
authors.lastname: Huang
authors.forename: Kuo-Wei
authors.initials: KW
authors.lastname: Lu
authors.forename: Tzyy-Leng
authors.initials: TL
authors.lastname: Horng
authors.forename: Win-Li
authors.initials: WL
authors.lastname: Lin
mesh_terms: D000465:Algorithms; D019540:Area Under Curve; D001692:Biological Transport; D002199:Capillary Permeability; D003198:Computer Simulation; D003911:Dextrans / Q000378:metabolism / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D006801:Humans; D046911:Macromolecular Substances / Q000378:metabolism; D008954:Models, Biological; D008962:Models, Theoretical; D053758:Nanoparticles; D009369:Neoplasms / Q000378:metabolism*; D014018:Tissue Distribution; D059016:Tumor Microenvironment
chemical_list: D003911:Dextrans; D046911:Macromolecular Substances
references.citation: J Clin Oncol. 1999 Nov;17(11):3540-5
references.pmid: 10550152
references.citation: Microvasc Res. 1986 May;31(3):288-305
references.pmid: 2423854
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4628-33
references.pmid: 11274375
references.citation: Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12
references.pmid: 9539785
references.citation: Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
references.pmid: 2946403
references.citation: J Control Release. 2001 Jul 6;74(1-3):193-202
references.pmid: 11489495
references.citation: Cancer Chemother Pharmacol. 1988;21(3):185-90
references.pmid: 3129204
references.citation: Mol Biol Cell. 2002 Feb;13(2):570-8
references.pmid: 11854413
references.citation: PLoS One. 2011;6(6):e20344
references.pmid: 21673952
references.citation: Cancer Chemother Pharmacol. 1989;23(5):279-82
references.pmid: 2523252
references.citation: Am J Pathol. 1995 May;146(5):1029-39
references.pmid: 7538264
references.citation: J Control Release. 2000 Mar 1;65(1-2):271-84
references.pmid: 10699287
references.citation: ACS Nano. 2012 May 22;6(5):4157-68
references.pmid: 22486623
references.citation: Am J Pathol. 2000 Apr;156(4):1363-80
references.pmid: 10751361
references.citation: Clin Cancer Res. 2002 Apr;8(4):1008-13
references.pmid: 11948107
references.citation: AJR Am J Roentgenol. 2001 Oct;177(4):747-53
references.pmid: 11566666
references.citation: Cancer Res. 2002 Dec 1;62(23):6831-6
references.pmid: 12460895
references.citation: Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14765-70
references.pmid: 8962129
references.citation: Biotechnol Bioeng. 2008 Oct 1;101(2):388-99
references.pmid: 18500767
references.citation: Cancer Res. 2003 Mar 15;63(6):1288-96
references.pmid: 12649189
references.citation: J Natl Cancer Inst. 2006 Mar 1;98(5):335-44
references.pmid: 16507830
references.citation: Eur J Pharm Biopharm. 2000 Jul;50(1):61-81
references.pmid: 10840193
references.citation: Cancer Res. 2012 Mar 15;72(6):1485-93
references.pmid: 22282664
references.citation: J Control Release. 2010 Sep 15;146(3):291-8
references.pmid: 20621645
references.citation: Cancer Res. 1987 Jun 15;47(12):3039-51
references.pmid: 3555767
references.citation: Microvasc Res. 1989 Jan;37(1):77-104
references.pmid: 2646512
references.citation: Pharm Res. 2010 Aug;27(8):1750-4
references.pmid: 20424894
references.citation: Br J Cancer. 2000 May;82(9):1513-8
references.pmid: 10789717
references.citation: Pharm Res. 2002 Sep;19(9):1310-6
references.pmid: 12403067
references.citation: PLoS One. 2012;7(10):e47453
references.pmid: 23082168
references.citation: Cancer Res. 1990 Aug 1;50(15):4478-84
references.pmid: 2369726
references.citation: Acc Chem Res. 2009 Aug 18;42(8):1141-51
references.pmid: 19555070
references.citation: Mol Biol Cell. 1997 Jan;8(1):59-71
references.pmid: 9017595
references.citation: Biophys J. 2010 Sep 8;99(5):1342-9
references.pmid: 20816045
references.citation: Nat Rev Drug Discov. 2003 May;2(5):347-60
references.pmid: 12750738
references.citation: Clin Pharmacokinet. 1997 Sep;33(3):161-83
references.pmid: 9314610
references.citation: FASEB J. 2008 Jan;22(1):276-84
references.pmid: 17761521
references.citation: Cancer Res. 2000 May 1;60(9):2497-503
references.pmid: 10811131
references.citation: Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2426-31
references.pmid: 21245339
references.citation: Cancer Chemother Pharmacol. 1997;40(1):11-8
references.pmid: 9137523
references.citation: Adv Drug Deliv Rev. 2001 Mar 23;47(1):113-31
references.pmid: 11251249
references.citation: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references.pmid: 15688077